Larvol Delta - Riskadaptive-management-of-stage-III-NSCLC-in-the-perioperative-immunotherapy-era-a-critical-synthesis-and-clinical-framework

Imfinzi (durvalumab) - AstraZeneca

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

http://www.ncbi.nlm.nih.gov/pubmed/42775057

Sep 24, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next